Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
Subscribe To Our Newsletter & Stay Updated